메벤다졸 - 알벤다졸 투여량

Table 1

Antitumorigenicity of benzimidazole anthelmintics in clinical aspects

StageCancer typePurposeMethodsResults and ongoingRef.

Phase 1	36 patients with refractory solid tumors	Maximum-tolerated dose	Albendazole: p.o. on a day 1–14 of a 3-weekly cycle, from 400 mg b.d. to 1,200 mg b.d.	2,400 mg/day from 1,200 mg b.d.	(95)
				Decreased plasma VEGF
				Patients (16%) had a tumor marker response with a fall of at least 50%
				Adverse effects: myelosuppression, fatigue and mild gastrointestinal upset
Case report	74-year-old man with metastatic colon cancer	Treatment for significant progression in the lungs and abdominal lymph nodes with new partly, poorly defined liver metastases	Mebendazole: 100 mg b.d. for 6 wk	Near complete remission of the metastases in the lungs and lymph nodes and a good partial remission in the liver	(96)
	48-year-old man with adrenocortical carcinoma	Treatment for failure or intolerance to conventional treatments with mitotane, 5-fluorouracil, streptozotocin, bevacizumab, and radiation therapy	Mebendazole: 100 mg b.d. for 19 months	Regression of hepatic metastatic lesions and subsequently remained stable for 19 months, but progressed after 24 months	(97)
				No clinically adverse effects; quality of life was satisfactory
Phase 1	A patient with hepatocellular carcinoma with metastasis	Evaluation of albendazole	Albendazole: 10 mg/kg/day, p.o. in 2 divided doses for 28 days	Stabilization of the disease, but because of neutropenia, treatment was stopped on day 19	(98)
	8 patients with colorectal cancer with metastasis			Decreased carcinoembryonic antigen (CEA) in 2 patients and stabilized in 3 patients, an initial stabilization (5–10 days) in 2 patients	(98)
				No significant changes in liver and kidney function tests, but neutropenia in 2 patients
Phase 1	24 high-grade glioma	Mebendazole in newly diagnosed high-grade glioma patients receiving temozolomide	Mebendazole: 500 mg chewable tablets with meals, p.o. 3 times every day on 28-day cycle	Study period: April 4, 2013 to September 2025
NCT01729260				Location: The Johns Hopkins Hospital, Baltimore, Maryland, United States
NCT02644291	21 high-grade glioma	Phase I study of mebendazole therapy for recurrent/progressive pediatric brain tumors	Mebendazole: 500 mg chewable tablets, 3 divided doses with meals	Study period: May 2016 to June 2022
				Location: Johns Hopkins All Children's Hospital
				Saint Petersburg, Florida, United States
				Johns Hopkins University School of Medicine
				Baltimore, Maryland, United States
Phases 1/2	36 low- and high-grade glioma	A phase I study of mebendazole for the treatment of pediatric gliomas	Mebendazole: 50, 100, and 200 mg/kg/day, p.o. and b.d. for 70 wk for low-grade glioma patients and 48 wk for high-grade glioma patients	Study period: October 22, 2013 to April 2020
NCT01837862				Location: Cohen Children's Medical Center of New York, New Hyde Park, New York, United States
Phase 2	250 patients with malignant disease that is considered untreatable, progressive and fatal	Clinical evaluation of a new form of cancer therapy based on the principles of atavistic metamorphosis (atavistic chemotherapy)	Anti-bacterial, anti-fungal, anti-protozoal agents: anti-cancer properties of albendazole and mebendazole	Study period: July 2011 to December 31, 2023
NCT02366884				Location: Dr. Frank Arguello Cancer Clinic
				San Jose del Cabo, Baja California Sur, Mexico
				Instituto de Ciencia y Medicina Genomica
				Torreon, Coahuila, Mexico
Phase 3	40 patients with stage 4 colorectal cancer	Mebendazole as adjuvant treatment for colon cancer	Mebendazole	Study period: April 1, 2019 to December 2028
NCT03925662				Location: Sherief Abd-Elsalam, Cairo, Egypt
NCT02201381	207 participants with cancer	Study of the safety, tolerability and efficacy of metabolic combination treatments on cancer (METRICS)	Mebendazole: 100 mg, p.o. and u.i.d. for study duration	Study period: May 22, 2017 to May 22, 2022
				Location: Care Oncology Clinic, London, United Kingdom

b.d., twice daily; p.o., oral administration; u.i.d., once daily dosage.

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458798/